Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BEAT

BioTelemetry (BEAT) Stock Price, News & Analysis

BioTelemetry logo

About BioTelemetry Stock (NASDAQ:BEAT)

Key Stats

Today's Range
$2.40
$2.60
50-Day Range
$71.46
$72.27
52-Week Range
$27.35
$73.10
Volume
59,263 shs
Average Volume
94,103 shs
Market Capitalization
$66.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

BioTelemetry Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
37th Percentile Overall Score

BEAT MarketRank™: 

BioTelemetry scored higher than 37% of companies evaluated by MarketBeat, and ranked 739th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioTelemetry has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioTelemetry has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioTelemetry's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioTelemetry is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioTelemetry is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioTelemetry has a P/B Ratio of 13.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about BioTelemetry's valuation and earnings.
  • Percentage of Shares Shorted

    0.80% of the float of BioTelemetry has been sold short.
  • Short Interest Ratio / Days to Cover

    BioTelemetry has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioTelemetry has recently increased by 24.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioTelemetry does not currently pay a dividend.

  • Dividend Growth

    BioTelemetry does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.80% of the float of BioTelemetry has been sold short.
  • Short Interest Ratio / Days to Cover

    BioTelemetry has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioTelemetry has recently increased by 24.52%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 1 people have searched for BEAT on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioTelemetry insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,381.00 in company stock.

  • Percentage Held by Insiders

    20.85% of the stock of BioTelemetry is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.77% of the stock of BioTelemetry is held by institutions.

  • Read more about BioTelemetry's insider trading history.
Receive BEAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioTelemetry and its competitors with MarketBeat's FREE daily newsletter.

BEAT Stock News Headlines

HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
HeartBeam Reports Third Quarter 2024 Results
Breaking News: Tesla headed to $500…
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
See More Headlines

BEAT Stock Analysis - Frequently Asked Questions

BioTelemetry, Inc. (NASDAQ:BEAT) posted its quarterly earnings results on Wednesday, August, 14th. The medical research company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03.

BioTelemetry (BEAT) raised $16 million in an initial public offering on Thursday, November 11th 2021. The company issued 2,750,000 shares at a price of $5.50-$6.50 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioTelemetry investors own include NVIDIA (NVDA), Meta Platforms (META), Bristol-Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), PayPal (PYPL) and AbbVie (ABBV).

Company Calendar

Last Earnings
8/14/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/19/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:BEAT
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+222.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.61 per share

Miscellaneous

Free Float
21,105,000
Market Cap
$66.14 million
Optionable
Not Optionable
Beta
-0.98
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:BEAT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners